Everything below concerns GLP-1 analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Cameron and Pauling wrote many technical papers and a popular book, Cancer and Vitamin C, that discussed their observations. Pauling made vitamin C popular with the public and eventually published two studies of a group of 100 allegedly terminal patients that claimed vitamin C increased survival by as much as four times compared to untreated patients. A re-evaluation of the claims in 1982 found that the patient groups were not actually comparable, with the vitamin C group being less sick on entry to the study, and judged to be "terminal" much earlier than the comparison group. Later clinical trials conducted by the Mayo Clinic led by oncologist Dr. Edward T. Creagan also concluded that high-dose (10,000 mg) vitamin C was no better than placebo at treating cancer and that there was no benefit to high-dose vitamin C. The failure of the clinical trials to demonstrate any benefit resulted in the conclusion that vitamin C was not effective in treating cancer; the medical establishment concluded that his claims that vitamin C could prevent colds or treat cancer were quackery. Pauling denounced the conclusions of these studies and handling of the final study as "fraud and deliberate misrepresentation", and criticized the studies for using oral, rather than intravenous vitamin C (which was the dosing method used for the first ten days of Pauling's original study).
Reception to the advertisement was mixed, as some social media users thought its mention of genetics evoked eugenicist ideas. The Dunkin' campaign launched less than a week after American Eagle launched its campaign "Sydney Sweeney Has Great Jeans", which led to similar backlash. On February 8, 2026, during Super Bowl LX, Ben Affleck appeared in a commercial that parodies Good Will Hunting, a film that Affleck co-wrote and starred in, as a 1990s sitcom. He portrays "Will Dunkin'" a parody of Damon's character, "Will Hunting", where he's cast alongside 1990s sitcom stars such as Jason Alexander, Jennifer Aniston, Jasmine Guy, Alfonso Ribeiro, Matt LeBlanc, and Jaleel White. Tom Brady also appears in the commercial.
Such systems may use taxonomic thesauri to track accepted names and synonyms and to keep checklists aligned with changing taxonomy. Hardisty and colleagues have proposed the concept of "digital extended specimens" as an infrastructure for linking biodiversity records derived from physical specimens to a broader network of related digital objects and third-party data resources. Digitization improves access to specimen data, but it cannot by itself resolve cryptic diversity, which often requires direct examination and sequencing of preserved material. Despite these advances, many regions, particularly in the tropics, still lag behind in collecting and digitizing fungal diversity.
=== Insulin pricing === In January 2019, lawmakers from the United States House of Representatives sent letters to Eli Lilly and other insulin manufacturers asking for explanations for rapidly raising insulin prices. The annual cost of insulin for people with type 1 diabetes in the US almost doubled from $2,900 to $5,700 over the period from 2012 to 2016. Renewed attention was brought to Eli Lilly's pricing of insulin in November 2022, after a verified Twitter account impersonating Eli Lilly posted on Twitter that insulin would now be free. The following year, the company announced that it would be reducing the out-of-pocket price of insulin to $35 a month. The company also stated that it would lower the price of Humalog from $275 a month to $66 and that it would offer insulin glargine at a 78% discount compared to rival company Sanofi. Despite this, the reduced costs will not apply to Eli Lilly's newer brands of insulin, and the company's pricing is still significantly higher than it was several decades prior.
==== Others ==== Alfatradiol (Avicis, Avixis, Ell-Cranell Alpha, Pantostin) – oral – alopecia – dual weak estrogen and 5α-reductase inhibitor Minoxidil/finasteride (MorrF) – topical – alopecia – combination of minoxidil (potassium channel opener) and finasteride (5α-reductase inhibitor) Nepidermin (Easyef; DWP-401) – topical – alopecia – recombinant human epidermal growth factor (rhEGF) or epidermal growth factor receptor (EGFR) agonist
Sources: en.wikipedia.org
=== Permanent hair removal === Electrology has been practiced in the United States since 1875. It is approved by the FDA. This technique permanently destroys germ cells responsible for hair growth by way of the insertion of a fine probe into the hair follicle and the application of a current adjusted to each hair type and treatment area. Electrology is the only permanent hair removal method recognized by the FDA.
The pre-mRNA processing at the 3' end of the RNA molecule involves cleavage of its 3' end and then the addition of about 250 adenine residues to form a poly(A) tail. The cleavage and adenylation reactions occur primarily if a polyadenylation signal sequence (5'- AAUAAA-3') is located near the 3' end of the pre-mRNA molecule, which is followed by another sequence, which is usually (5'-CA-3') and is the site of cleavage. A GU-rich sequence is also usually present further downstream on the pre-mRNA molecule. More recently, it has been demonstrated that alternate signal sequences such as UGUA upstream off the cleavage site can also direct cleavage and polyadenylation in the absence of the AAUAAA signal. These two signals are not mutually independent, and often coexist. After the synthesis of the sequence elements, several multi-subunit proteins are transferred to the RNA molecule. The transfer of these sequence specific binding proteins cleavage and polyadenylation specificity factor (CPSF), Cleavage Factor I (CF I) and cleavage stimulation factor (CStF) occurs from RNA Polymerase II. The three factors bind to the sequence elements. The AAUAAA signal is directly bound by CPSF. For UGUA dependent processing sites, binding of the multi protein complex is done by Cleavage Factor I (CF I). The resultant protein complex formed contains additional cleavage factors and the enzyme Polyadenylate Polymerase (PAP). This complex cleaves the RNA between the polyadenylation sequence and the GU-rich sequence at the cleavage site marked by the (5'-CA-3') sequences.
=== Early history === The club traces its origins to a pair of clubs founded in 1904: Freiburger Fußballverein 04 was organised in March of that year; FC Schwalbe Freiburg just two months later. Both clubs underwent name changes, with Schwalbe becoming FC Mars in 1905, Mars becoming Union Freiburg in 1906, and FV 04 Freiburg becoming Sportverein Freiburg 04 in 1909. Three years later, SV and Union formed Sportclub Freiburg, at the same time incorporating the griffin head. In 1918, after World War I, SC Freiburg entered a temporary arrangement with Freiburger FC to be able to field a full side called KSG Freiburg. The next year, SC Freiburg associated themselves with FT 1844 Freiburg as that club's football department, until 1928 when they left to enter into a stadium-sharing arrangement with PSV (Polizeisportverein) Freiburg 1924 that lasted until 1930 and the failure of PSV. SC Freiburg then started again with FT 1844 Freiburg in 1938. The club played first in the Bezirksliga Baden in 1928, then in the Gauliga Baden, from which they were relegated in 1934. At the end of World War II, Allied occupation authorities disbanded most existing organizations in Germany, including football and sports clubs. The clubs reconstituted themselves after about a year, but were required to take on new names in an attempt to disassociate them from Nazis. SC Freiburg was therefore briefly known as VfL Freiburg. By 1950, French-occupation authorities allowed the clubs to reclaim their old identities. Finally, in 1952, SC Freiburg left FT Freiburg behind again.
Boston Market Corporation, known as Boston Chicken until 1995, is an American fast casual restaurant chain headquartered in Newtown Township, Pennsylvania. Since 2020, it has been owned by Engage Brands, LLC, a company of Rohan Group. From 1985 to 1995, Boston Market was known as Boston Chicken, which rapidly expanded to over a thousand locations. By the late 1990s, the chain filed for bankruptcy and closed many stores until a few hundred remained. McDonald's purchased the chain in 2000. It was sold again in 2007, then in 2020. As of November 2020, the chain had approximately 342 company-owned restaurant locations in 28 states and Puerto Rico. In the 2020s the chain encountered legal troubles and went into a rapid decline to end 2024 with only 16 remaining stores. At its peak, Boston Market had its greatest presence in the Northeastern and Midwestern United States, as well as California, Florida, and Texas. Boston Market helped popularize rotisserie chicken and fast-casual dining, both of which remain popular nationally. While initially specializing in rotisserie chicken, the chain later branched out into other meats, including turkey, meatloaf, and ham. A typical meal paired a protein with sides like potatoes, creamed spinach, or mac & cheese, accompanied by a piece of corn bread. Stores also offered seasonal specials and sandwiches. Frozen meals and side dishes continue to be sold nationally under the Boston Market brand name in food markets.
== Chemistry == Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4-propionylpiperidine. It is usually available as the hydrochloride, which is a white powder. It is synthesized by alkylating (3-methoxyphenyl)acetonitrile with bis(2-chloroethyl)methylamine, followed by reaction with ethylmagnesium bromide, and finally O-demethylation with hydrobromic acid. Because of a strong vesicant nature of bis(2-chloroethyl)methylamine there are many other routes developed for obtaining ketobemidone. A route depicted below lays through first alkylating the same (3-methoxyphenyl)acetonitrile with 2-chloro-N,N-dimethylethylamine or 2-chloro-N-benzyl-N-methylethylamine. Next, those amines are alkylated once again using a mixed 1-bromo-2-chloroethane, thus completing the piperidine ring and obtaining a quaternary ammonium salt, which can be dequaternized using thiophenol salt (for N,N-dimethylammonium) or catalytic hydrogenation (for both compounds) to a common 4-(3-methoxyphenyl)-4-cyano-1-methyl-pyperidine. The latter yields ketobemidone after Grignard reaction with ethylmagnesium bromide and ether cleavage.
Sources: en.wikipedia.org
==== Inventory in spent nuclear fuel ==== 237Np is the only neptunium isotope produced in significant quantity in the nuclear fuel cycle, both by successive neutron capture by uranium-235 (which fissions most but not all of the time) and uranium-236, or (n,2n) reactions where a fast neutron occasionally knocks a neutron loose from uranium-238 or isotopes of plutonium. Over the long term, 237Np also forms in spent nuclear fuel as the decay product of americium-241. 237Np is considered to be one of the most mobile radionuclides at the site of the Yucca Mountain nuclear waste repository (Nevada) where oxidizing conditions prevail in the unsaturated zone of the volcanic tuff above the water table.
=== Cystic fibrosis === The human lung and saliva contain a wide range of antimicrobial compound including lactoperoxidase system, producing hypothiocyanite and lactoferrin, with hypothiocyanite missing in cystic fibrosis patients. Lactoferrin, a component of innate immunity, prevents bacterial biofilm development. The loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity is observed in patients with cystic fibrosis. In cystic fibrosis, antibiotic susceptibility may be modified by lactoferrin. These findings demonstrate the important role of lactoferrin in human host defense and especially in lung. Lactoferrin with hypothiocyanite has been granted orphan drug status by the EMEA and the FDA.
Nicotine also activates the sympathetic nervous system, acting via splanchnic nerves to the adrenal medulla, stimulating the release of epinephrine. Acetylcholine released by preganglionic sympathetic fibers of these nerves acts on nicotinic acetylcholine receptors, causing the release of epinephrine (and norepinephrine) into the bloodstream.
=== Direct measurement === Blood samples for BAC analysis are typically obtained by taking a venous blood sample from the arm. A variety of methods exist for determining blood-alcohol concentration in a blood sample. Forensic laboratories typically use headspace-gas chromatography combined with mass spectrometry or flame ionization detection, as this method is accurate and efficient. Hospitals typically use enzyme multiplied immunoassay, which measures the co-enzyme NADH. This method is more subject to error but may be performed rapidly in parallel with other blood sample measurements. In Germany, BAC is determined by measuring the serum level and then converting to whole blood by dividing by the factor 1.236. This calculation underestimates BAC by 4% to 10% compared to other methods.
Pentafluorophenyl (PFP) esters are chemical compounds with the generic formula RC(O)OC6F5. They are active esters derived from pentafluorophenol (HOC6F5). PFP esters are useful for attaching fluorophores such as fluorescein or haptens to primary amines in biomolecules. They also are valuable in laboratory peptide synthesis. Pentafluorophenyl esters produce amide bonds as effectively as succinimidyl esters and various similar agents do, but PFP esters are particularly useful because they are less susceptible to spontaneous hydrolysis during conjugation reactions.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.